Definium Therapeutics, Inc. - Common Shares (NQ:DFTX)

37.40 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Definium Therapeutics, Inc. - Common Shares

< Previous 1 2 3 Next >

Definium Therapeutics Announces New Employee Inducement Grants

September 28, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression ↗

September 24, 2026

Definium Therapeutics (NASDAQ:DFTX) Chief Medical Officer Dan Karlin said the company’s recent Phase III results for DT120 showed statistically significant improvements in generalized anxiety disorder,...

Via MarketBeat

Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study ↗

September 19, 2026

Definium Therapeutics (NASDAQ:DFTX) reported positive top-line results from Panorama, its second Phase III study of DT120 ODT 100 mcgs in generalized anxiety disorder, or GAD. The company said the...

Via MarketBeat

Definium Therapeutics (NASDAQ:DFTX) Slides After Q2 Loss Misses Estimates on Warrant Charge ↗

August 06, 2026

Via Chartmill

Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder

September 14, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces New Employee Inducement Grants

September 14, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026

September 13, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026

September 10, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results

September 08, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces New Employee Inducement Grants

August 31, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

August 26, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces New Employee Inducement Grants

August 17, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics’ DT120 Meets Phase III Goals in GAD Study ↗

August 13, 2026

Definium Therapeutics (NASDAQ:DFTX) reported positive top-line results from Voyage, its Phase III study evaluating a single 100 mcg dose of DT120 ODT for generalized anxiety disorder, or GAD. The...

Via MarketBeat

Wondering what's happening in today's pre-market session? ↗

August 12, 2026

Via Chartmill

Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder

August 12, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Q2 Earnings Call Highlights ↗

August 06, 2026

Definium Therapeutics (NASDAQ:DFTX) said it expects to report top-line results from its Phase III VOYAGE study of DT120 ODT in generalized anxiety disorder during the week of Aug. 10, following...

Via MarketBeat

Topics Earnings

Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

August 06, 2026

From Definium Therapeutics, Inc.

Via Business Wire

A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout

August 05, 2026

Issued on behalf of Helus Pharma (Nasdaq: HELP)

From USA News Group

Via GlobeNewswire

Definium Therapeutics Announces New Employee Inducement Grants

August 03, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

July 30, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces New Employee Inducement Grants

July 20, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology

July 16, 2026

From Definium Therapeutics, Inc.

Via Business Wire

New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)

July 14, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces New Employee Inducement Grants

July 06, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

June 30, 2026

EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END

Via FinancialNewsMedia

Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

June 30, 2026

Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity

From MarketNewsUpdates.com

Via GlobeNewswire

Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

June 25, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering

June 23, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics, Inc. Announces Proposed Public Offering

June 22, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Top movers analysis one hour before the close of the markets on 2026-06-22: top gainers and losers in today's session. ↗

June 22, 2026

Via Chartmill

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.